Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4+/CD8+ cells in COVID-19 patients

Asmaa M. Zahran, MDa, Hanaa Nafady-Hego, MDb, Khalid Ali Nasif, MDc,d, Amr Talat Mostafa, MD, Heba Ahmed Osman, MDa,b,c, Eptehal Mohammed Dongol, MDd, Abdelkader Ahmed Hashim, MDe, Ghada M. Abdelrazek, MD, Nehad Hassan Abd Elrahman, MD, Asmaa Nafady, MDf

Abstract
Coronavirus infectious disease 2019 (COVID-19) confirmed cases are characterized by T lymphopenia. Total apoptotic and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expressing cells among CD4+/CD8+ cells were analyzed in 24 COVID-19 patients (16 out-patients and 8 in-patients) and 18 healthy volunteers using flow cytometry to detect their possible role in T lymphopenia. Hospitalized patients did not show significant difference compared to non-hospitalized patients. While the percentage and absolute count of CD4+/CD8+ cells were significantly reduced in COVID-19 cases compared to healthy control (P < .05), the proportion of apoptotic and CTLA-4 expressing CD4+/CD8+ cells were significantly up-regulated in COVID-19 patients (P < .05). In addition, apoptotic and CTLA-4+/CD4+ cells were directly related to dyspnea duration, chest CT score, ferritin, and C-reactive protein and inversely correlated with platelet count in COVID-19 patients. While apoptotic and CTLA-4+/CD8+ cells were directly related to lymphocyte count in COVID-19 patients. The apoptotic and CTLA-4+ cells were directly related to each other in CD4+/CD8+ cells (P < .05). White blood cells (WBCs) (×10³/L), eosinophils (ratio and count), lymphocyte ratio, neutrophil ratio, neutrophil/lymphocyte ratio, neutrophil/CD4 ratio, neutrophil/CD8 ratio, CD4+ cells ratio, and CTLA-4+ cells percentage), and CD8+ cells (ratio, count, total apoptotic cell, and CD152+ cells) were all found to be significantly altered in association with COVID-19. Total lymphopenia and depletion of CD4+/CD8+ cells are characterizing COVID-19 patients. Increased apoptosis and CTLA-4 expression in CD4+/CD8+ cells in COVID-19 and their correlations with reduced cell count and severity indicators as CRP and ferritin can be used for diagnosis and follow up of the clinical severity. Our current study proposes promising future diagnostic and therapeutic targets.

Abbreviation:
CD4+ = cluster of differentiation 4+, CD8+ = cluster of differentiation 8+, COVID-19 = coronavirus infectious disease 2019 novel coronavirus, CRP = C reactive protein, CTLA-4 = cytotoxic T-lymphocyte antigen-4, FITC = fluoroisothiocyanate, PI = propidium iodide, RT-PCR = reverse transcriptase-polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2.

Keywords: apoptosis, COVID-19, CTLA-4 (CD152), infection, SARS-CoV-2

1. Introduction
Coronavirus infectious disease 2019 (COVID-19) is an ongoing pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most of the infected cases presented either with no or mild to moderate symptoms. Reports of severe cases were associated with a dysregulated immune response.[1–4] Attention is being paid to developing
novel therapeutic modalities, including those modulating the host immune system. Studying the influences of COVID-19 on immune cell specificity and functionality can produce clues to understanding the mechanism of the disease and suggest biomarkers that can be used as therapeutic targets in the COVID-19 setting.

Wuhan study assessed the immune response induced by COVID-19 in 452 laboratory-confirmed patients and showed CD4 lymphopenia more often in severe cases, with intact cytotoxic T cells and B cells. Later on, a number of reports came to support the same concept of increased neutrophil count at the expense of lymphocyte count that may be exhausted and damaged by COVID-19. Lessons from previous viral epidemics and animal experiments in the current pandemic show possible protective T cell responses against SARS-CoV-2 infection.

Lymphocyte exhaustion may be due to the dysfunction of apoptotic pathways of the host cell and/or the immune system that interacts with these pathways. Previous reports from other coronaviruses revealed that these viruses induce apoptosis during their replication. An increase in apoptosis was reported among mononuclear cells from COVID-19 patients as CD4+/CD8+ apoptosis and the expression of CTLA-4 in COVID-19 patients with both ligands with higher affinity and avidity than CD28. CD8+ T cells, which mediate opposing functions in T-cell activation. Both receptors share a pair of ligands, CD80 and CD86, expressed on antigen-presenting cells’ surface. CD4+ and CD8+ T cells, which mediate opposing functional activities in T-cell activation. Both receptors share a pair of ligands, CD80 and CD86, expressed on antigen-presenting cells’ surface. CD4+ and CD8+ T cells, which mediate opposing functional activities in T-cell activation. Both receptors share a pair of ligands, CD80 and CD86, expressed on antigen-presenting cells’ surface.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and CD28 are homologous receptors expressed by both CD4+ and CD8+ T cells, which mediate opposing functions in T-cell activation. Both receptors share a pair of ligands with higher affinity and avidity than CD28 and act as an antagonist of CD28-mediated co-stimulation. Robins et al showed the attribution of T cell exhaustion to the elevation of the CTLA-4 marker on the peripheral blood mononuclear cells of critically ill COVID-19 patients. Data on the factors standing behind lymphopenia and T cell exhaustion in COVID-19 patients remains limited. We aimed to assess the CD4+/CD8+ apoptosis and the expression of CTLA-4 in COVID-19 patients and their relation to disease severity.

2. Patients and Methods
2.1. Patient selections
A prospective case-control study included 24 patients who were admitted to Qena University Hospital, Upper Egypt during the period from August 2020 to September 2020. With a confirmed positive result for SARS-CoV-2 using reverse transcriptase-polymerase chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab tested in accredited laboratories.

The patients were 21 males (87.5%) and 3 females (12.5%). Their mean age was 30.6 ± 14. The data was compared with that of 18 age and sex-matched healthy individuals, their mean age was 34.7 ± 12.5. Lessons from previous viral epidemics and animal experiments in the current pandemic show possible protective T cell responses against SARS-CoV-2 infection.

The study included 24 patients with a confirmed positive test for SARS-CoV-2. The patients were 21 males (87.5%) and 3 females (12.5%). Their mean age was 30.6 ± 14. The data was compared with that of 18 age and sex-matched healthy individuals, their mean age was 34.7 ± 12.5. Statistical analysis was performed with IBM SPSS Statistics 21. The data were tested for normality using Shapiro–Wilk test based on P < .05 Mann–Whitney U test was used to compare continuous variables, and Chi-square tests were used to compare categorical, and ordinal variables between the studied groups and for P > .05 Student t test was used. Correlations were performed via the Pearson correlation coefficient. To calculate the odd’s ratio, a logistic regression model was used for factors associated with infection. To start with, a univariable logistic regression was done and variables significant at a P < .2 were included in the multivariable model. Statistical significance was set at P < .05. The sample size in this study was calculated by “EBI” program at power 80%, with confidence 95.0%, α 0.5 equal 42 patients divided in 2 groups.

2.2. Chest CT
Chest CT was done to diagnose COVID-19 pneumonia which revealed multisegmental consolidative areas with a score 18 c or multisegmental peripheral ground glass opacities with a score 3 A according to the modified total severity scoring system “Supplemental Digital Content (Figure S1, Supplemental Digital Content 1, http://links.lww.com/MD/H352).”

2.3. Flow cytometric detection of apoptosis
Peripheral blood samples were collected from all participants in ethylenediaminetetraacetate acid vacutainer tubes for the flow cytometry.

2.3.1. Flow cytometric detection of apoptosis of CD4+/CD8+ cells. Apoptosis was measured by the Annexin V (AV) fluorosoroiosihoxyanate (FITC) binding assay according to the manufacturer’s instructions (BD Biosciences, San Jose, CA). A 100 μL of whole blood was stained with 10 μL of peridinium-chlorophyl-protein-conjugated CD8 and APC-conjugated CD4, washed twice with 2mL of phosphate-buffered saline and red blood cells were lysed. The cells were washed and re-suspended in 100 μL of the AV-conjugate binding buffer, to which 10 μL of FITC-conjugated AV and 10 μL of Propidium iodide (PI) were added. After incubation for 15 minutes, 400 μL of the binding buffer was added. Analysis was done using FACScalibur flow cytometry (BD Biosciences, San Jose, CA). Anti-human IgG was used as an isotype-matched negative control with each sample. A forward and side scatter histogram was used to identify the lymphocyte population. Then, the percentages of CD4+ and CD8+ cells were assessed in the lymphocyte population, and the total percentage of apoptotic cells [AV − PI early apoptotic and AV + PI late apoptotic cells] was then calculated among the CD4+ and CD8+ cells. “Supplemental Digital Content (Figure S2, Supplemental Digital Content 2, http://links.lww.com/MD/H353).”

2.3.2. CD4+/CD8+ expression of CTLA-4 (CD152). A total of 10 μL peripheral blood was stained with 10 μL of FITC conjugated CD152, peridinium-chlorophyl-protein-conjugated-CD8, and APC conjugated- CD4 (Becton-Dickinson, San Jose, CA). Isotype controls were included for each sample. A total of 50,000 events were acquired for each sample using a FACScalibur flow cytometer. Then, the percentages of CD152 were assessed in the CD4+ and CD8+ cells.

2.4. Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics 21. The data were tested for normality using Shapiro–Wilk test based on P < .05 Mann–Whitney U test was used to compare continuous variables, and Chi-square tests were used to compare categorical, and ordinal variables between the studied groups and for P > .05 Student t test was used. Correlations were performed via the Pearson correlation coefficient. To calculate the odd’s ratio, a logistic regression model was used for factors associated with infection. To start with, a univariable logistic regression was done and variables significant at a P > .2 were included in the multivariable model. Statistical significance was set at P < .05. The sample size in this study was calculated by “EBI” program at power 80%, with confidence 95.0%, α 0.5 equal 42 patients divided in 2 groups.

3. Results
3.1. Demographic data of the studied group
The study included 24 patients with a confirmed positive test for SARS-CoV-2. The patients were 21 males (87.5%) and 3 females (12.5%). Their mean age was 30.6 ± 14. The data was compared with that of 18 age and sex-matched healthy individuals, their mean age was 34.7 ± 12.5 (P = .326) whose SARS-CoV-2 RT-PCR test showed negative results.
3.2. Clinical and laboratory finding in COVID-19 patients

We studied 24 COVID-19 patients, 25% gave a clear history of exposure to a confirmed COVID-19 case. Most of them had fever (87.5%), cough (70.8%), and dyspnea (50%), and a few were complaining of anosmia (20.8%) and diarrhea (16.7%). Chest CT showed minimal ground glass (<25%) in 3 patients (12.5%), 3 others showed moderate ground glass (>25%), and 5 patients (20.8%) had acute respiratory distress syndrome. Patients were further stratified according to their hospital status into in-patients (No. 8) and out-patients (No. 16) to address any clinical or laboratory differences among them. The results revealed that dyspnea was commoner among in-patients than out patients ($P = .014$), in addition worse CT findings were commoner among in-patients than out patients ($P = .001$) (Table 1).

Laboratory finding did not significantly vary among COVID-19 patients based on their hospital status, ferritin level was higher in in-patients than in out-patients ($P = .018$) (Table 1).

3.3. Baseline laboratory features of COVID-19 infected patients

On comparing COVID-19 cases with healthy control, the mean white blood cell (WBC) count significantly decreased in COVID-19 patients (5.6, confidence interval [CI] (4.6, 6.7) and 7.3, CI (4.6, 6.7), $P = .01$). Moreover, mean lymphocyte count was considerably lower in COVID-19 patients (1.04, CI (0.88, 1.2) vs 3.1, CI (2.6, 3.7), $P < .001$), no significant alteration was detected in the neutrophil count between patients and healthy controls. The CRP mean level in COVID-19 patients was 15.8, CI (9.2, 22). Additionally, the mean D-dimer level was 422.9 ± 53 mg/L, and that of ferritin was 45.24, CI (280.9, 627.5) ng/mL (Table 2).

Interestingly, a marked decrease in the mean neutrophil/lymphocyte ratio, neutrophil/CD4 ratio, neutrophil/CD8 ratio but not CD4/CD8 ratio was found in COVID-19 patients when compared with that of healthy controls (Table 2).

### Table 1

| Clinical and laboratory characteristics of 24 COVID-19 patients. | In-patients | Out-patients | $P$ value |
| --- | --- | --- | --- |
| **Clinical characteristics** | | | |
| Fever (No. 21 (87.5%)) | 7 | 14 | .723 |
| Anosmia (No. 5 (20.8%)) | 0 | 5 | .103 |
| Dyspnea (No. 12 (50%)) | 7 | 5 | .218 |
| Cough (No. 17 (70%)) | 10 | 7 | .165 |
| GIT disturbances (No. 4 (16.7%)) | 2 | 2 | .001 |
| **Chest CT** | | | .001 |
| Free (No. 13 (54.2%)) | 1 | 12 | |
| Minimal ground glass <25% (No. 3 (12.5%)) | 0 | 3 | |
| Moderate ground glass >25% (No. 3 (12.5%)) | 2 | 1 | |
| >Ground glass or ARDS (No. 5 (20.8%)) | 5 | 0 | |
| **Laboratory characteristics** | | | |
| WBCs ($×10^3/µL$) | 6, 95% CI (4.7, 7.9) | 5.5, 95% CI (4.1, 6.9) | .601 |
| Eosinophils ratio | 2.95, CI (0.5, 3.5) | 2.6, 95% CI (1.3, 3.9) | .851 |
| Eosinophils count ($×10^3/µL$) | 0.1, 95% CI (0.04, 0.1) | 0.1, 95% CI (0.08, 0.2) | .383 |
| Lymphocyte ratio | 21.95, CI (11, 30) | 20.7, 95% CI (11.5, 30) | .996 |
| Lymphocyte count ($×10^3/µL$) | 1.1, 95% CI (0.7, 1.5) | 1.95, CI (0.8, 1.2) | .339 |
| Neutrophil ratio | 68, 95% CI (59, 78) | 68, 95% CI (62, 74) | .944 |
| Neutrophil count ($×10^3/µL$) | 4.2, 95% CI (2.5, 5.9) | 3.9, 95% CI (2.7, 5) | .714 |
| Hemoglobin g/dL | 14.7, 95% CI (13, 16) | 14.95, CI (13, 15) | .55 |
| Platelet count | 329, 95% CI (293, 363) | 348, 95% CI (323, 368) | .707 |
| D dimer (mg/L) | 514, 95% CI (211, 817) | 377, 95% CI (236, 518) | .202 |
| CRP (mg/dL) | 667, 95% CI (201, 1134) | 348, 95% CI (196, 499) | .018 |
| Ferritin (ng/mL) | 667, 95% CI (201, 1134) | 348, 95% CI (196, 499) | .018 |
| Neutrophil/lymphocyte ratio | 0.395, CI (0.1, 0.5) | 0.395, CI (0.2, 0.5) | .395 |
| Neutrophil/CD4 ratio | 0.395, CI (0.1, 0.5) | 0.395, CI (0.2, 0.5) | .395 |
| Neutrophil/CD8 ratio | 0.07, 95% CI (0.03, 0.1) | 0.06, 95% CI (0.04, 0.09) | .861 |
| CD4/CD8 ratio | 1.495, CI (1.4, 1.8) | 1.695, CI (1.4, 1.9) | .712 |
| CD4+ cells Absolute count ($×10^9/L$) | 0.4, 95% CI (0.2, 0.5) | 0.3, 95% CI (0.2, 0.5) | .187 |
| Relative to lymphocyte count (%) | 47, 95% CI (44, 49) | 48, 95% CI (43, 52) | .805 |
| Total apoptotic CD4+ cells (%) | 16, 95% CI (14, 19) | 16, 95% CI (13, 18) | .395 |
| Total apoptotic CD4+ cells count | 0.06, 95% CI (0.04, 0.08) | 0.04, 95% CI (0.03, 0.05) | .137 |
| CD4+ CTLA-4+ cells (%) | 13.2, 95% CI (10.6, 15.8) | 11.7, 95% CI (10.2, 13.3) | .355 |
| CD4+ CTLA-4+ cells count | 0.04, 95% CI (0.03, 0.06) | 0.03, 95% CI (0.03, 0.04) | .09 |
| CD8+ cells Absolute count ($×10^7/L$) | 0.2, 95% CI (0.2, 0.3) | 0.2, 95% CI (0.1, 0.2) | .103 |
| Relative to lymphocyte count (%) | 30, 95% CI (28, 32) | 30, 95% CI (27, 33) | .882 |
| Total apoptotic CD8+ cells (%) | 8.7, 95% CI (8, 9) | 8.95, CI (8.6, 11.1) | .19 |
| Total apoptotic CD8+ cells count | 0.02, 95% CI (0.1, 0.03) | 0.02, 95% CI (0.01, 0.02) | .35 |
| CD8+ CTLA-4+ cells (%) | 8.3, 95% CI (5.2, 11.5) | 8.2, 95% CI (6.4, 10.1) | .925 |
| CD8+ CTLA-4+ cells count | 0.02, 95% CI (0.01, 0.03) | 0.01, 95% CI (0.01, 0.02) | .251 |

ARDS = acute respiratory distress syndrome, CD4+ = cluster of differentiation 4+, CD8+ = cluster of differentiation 8+, CI = confidence interval, COVID-19 = coronavirus infectious disease 2019 novel coronavirus, CRP = C-reactive protein, CT = computed tomography, CT LA-4+ = cytotoxic T-lymphocyte antigen-4+, GIT = gastrointestinal tract, WBCs = white blood cells.
3.4. Percentages of the total apoptotic and CD152 expressing CD4<sup>+</sup>/CD8<sup>+</sup> cells in COVID-19 patients and healthy controls

As presented in Figure 1A, both the CD4<sup>+</sup> cells percentage (a) and count (b) showed marked reduction in COVID-19 patients when compared with the control group (50.3 ± 9.4 vs 56.8 ± 7.8, \( P = .014 \) and 0.3 ± 0.14 vs 1.2 ± 0.51, \( P < .0001 \), respectively). Meanwhile, a marked increase was detected in the levels of both the total apoptotic CD4<sup>+</sup>-cell percentage (c) and absolute count (d) (16.5 ± 3.7 vs 1.3 ± 0.3, \( P < .0001 \) and 0.06 ± 0.03 vs 0.02 ± 0.01, \( P < .0001 \), respectively). An increase in the CD152 expressing CD4<sup>+</sup>-cell percentage (e) was also seen in the COVID-19 patients in comparison with the controls (12.2 ± 2.8 vs 6.1 ± 3.2, \( P < .0001 \)), while the absolute count of CD152 expressing CD4<sup>+</sup> cells could not reach a significant increase due to CD4 lymphopenia in COVID-19 patients (0.04 ± 0.02 vs 0.07 ± 0.03, \( P = .003 \)) (f) (Fig. 1A).

Likewise in Figure 1B, both the CD8<sup>+</sup>-cells percentage (a) and absolute count showed an obvious fall in COVID-19 patients than in the control group (28.7 ± 5.4 vs 33.6 ± 7.2, \( P = .02 \) and 0.2 ± 0.07 vs 0.7 ± 0.4, \( P < .0001 \), respectively). Contrariwise, a marked increase was noticed in the levels of both the total apoptotic CD8<sup>+</sup>-cell percentage (c) and absolute count (d) (9.8 ± 2 vs 2.2 ± 2.7, \( P < .0001 \) and 0.019 ± 0.01 vs 0.01 ± 0.01, \( P = .002 \), respectively). The proportion of CD152 expressing CD8<sup>+</sup>-cell (e) was higher in the COVID-19 patients in comparison with the controls (8.2 ± 3 vs 4 ± 2.3, \( P < .0001 \)), while the calculated absolute CD152 expressing CD8<sup>+</sup>-cell count significantly reduced in COVID-19 patients as it is affected by CD8 lymphopenia (0.02 ± 0.01 vs 0.03 ± 0.01, \( P = .003 \)) (Fig. 1B).

Table 2: Baseline laboratory features of COVID-19 infected patients.

| Features                  | Patients        | Controls        | P value |
|---------------------------|-----------------|-----------------|---------|
| WBCs (×10<sup>3</sup>/µL) | 5.6, CI (4.6, 6.7) | 7.3, CI (4.6, 6.7) | .011    |
| Eosinophils ratio         | 2.4, CI (1.5, 3.3) | 4.0, CI (3.2, 4.8) | .003    |
| Eosinophils count (×10<sup>9</sup>/µL) | .12, CI (0.8, 1.5) | .29, CI (0.8, 1.5) | .0001   |
| Lymphocyte count (×10<sup>3</sup>/µL) | 1.04, CI (1.88, 1.2) | 3.1, CI (2.6, 3.7) | .0001   |
| Neutrophil count (×10<sup>3</sup>/µL) | 4.1, CI (3.1, 4.8) | 3.3, CI (2.8, 3.8) | .426    |
| D dimer (mg/L)            | 422.9, CI (297.7, 548) | –, CI (–, –) |         |
| CRP (mg/dL)               | 15.8, CI (9.2, 22.2) | –, CI (–, –) |         |
| Ferritin (ng/mL)          | 454.24, CI (280.9, 627.5) | –, CI (–, –) |         |
| Neutrophil/lymphocyte ratio | 4.1, CI (3.2, 4.4) | 1.2, CI (3.5, 1.4) | .0001   |
| Neutrophil/CD4 ratio      | 13.6, CI (10.7, 16.5) | 3.1, CI (2.5, 3.8) | .0001   |
| Neutrophil/CD8 ratio      | 21.1, CI (16.9, 16.5) | 5.4, CI (4.2, 6.7) | .0001   |
| CD4/CD8 ratio             | 1.62, CI (1.43, 1.82) | 1.81, CI (1.5, 2.13) | .46     |

Results expressed as mean, 95% confidence interval for mean (CI), Mann–Whitney U test, a P value is significant if <.05.

CD4 = cluster of differentiation 4, CD8 = cluster of differentiation 8, COVID-19 = coronavirus infectious disease 2019 novel coronavirus, CRP = C-reactive protein, WBCs = white blood cells.

Figure 1: Percentages of the total apoptotic and CD152 expressing CD4<sup>+</sup> and CD8<sup>+</sup> cells in COVID-19 patients and healthy controls. (A) CD4<sup>+</sup>-cells percentage (a) and count (b), CD4<sup>+</sup>-total apoptotic cell percentage (c), CD4<sup>+</sup>-total apoptotic absolute count (d), CD4<sup>+</sup>-CD152<sup>+</sup>-ratio (e), and CD4<sup>+</sup>-CD152<sup>+</sup>-absolute count (f) in the COVID-19 patients and healthy controls. (B) CD8<sup>+</sup>-cells percentage (a) and count (b), CD8<sup>+</sup>-total apoptotic cell percentage (c), CD8<sup>+</sup>-total apoptotic absolute count (d), CD8<sup>+</sup>-CD152<sup>+</sup>-ratio (e), and CD8<sup>+</sup>-CD152<sup>+</sup>-absolute count (f) in the COVID-19 patients and healthy controls. CD4<sup>+</sup> = cluster of differentiation 4, CD8<sup>+</sup> = cluster of differentiation 8, COVID-19 = coronavirus infectious disease 2019 novel coronavirus.
3.5. Correlations of total apoptotic cells and clinical/laboratory parameters

Table 3 shows that in COVID-19 patients: the total CD4+ apoptotic cell count negatively correlated with platelet count and increased with higher ferritin and CRP ($R^2 = 0.269, P = .009$; $R^2 = 0.276, P = .008$ and $R^2 = 0.219, P = .021$, respectively). In the control group: the total CD4+ apoptotic cell count proportionally correlated with WBCs and lymphocyte count ($R^2 = 0.444, P = .003$ and $R^2 = 0.218, P = .05$, respectively) and negatively correlate with neutrophil/lymphocyte ratio ($R^2 = 0.333, P = .012$).

Interestingly, while WBCs proportionally correlate with CD8+ apoptotic cell count in healthy control, CD8+ apoptotic cell count proportionally correlated with lymphocyte count in both healthy control and COVID-19 patients ($WBCs: R^2 = 0.537, P = .001$ and $R^2 = 0.117, P = .002$, respectively; lymphocyte count: $R^2 = 0.699, P < .0001$ and $R^2 = 0.601, P < .0001$). Neutrophil/lymphocyte ratio negatively correlated with CD8+ apoptotic cell count in health control only ($R^2 = 0.355, P = .012$) (Table 3).

3.6. Correlations of CD4+/CD8+ expressing CTLA-4 (CD152) cells and laboratory parameters

Table 3 shows that CD4+ CTLA-4+ cell count negatively correlated with platelet count and positively correlate with CRP in COVID-19 patients ($R^2 = 0.283, P = .008$ and $R^2 = 0.164, P = .05$, respectively).

Interestingly, CD8+ CTLA-4+ cell count proportionally correlated with lymphocyte count ($R^2 = 0.346, P = .014$ in COVID-19 patients, and proportionally correlate with WBCs ($R^2 = 0.465, P = .002$), neutrophil count ($R^2 = 0.354, P = .009$) and lymphocyte count ($R^2 = 0.234, P = .014$) in healthy control (Table 3). Both apoptotic and CTLA-4+ CD4+ cells were directly related to dyspnea duration, chest CT score in COVID-19 cases (Apopotic CD4+: dyspnea duration: $R^2 = 0.375, P = .001$ and

### Table 3

|                          | COVID-19 patients | Healthy controls |
|--------------------------|-------------------|------------------|
|                          | r-factor | P-value | r-factor | P-value |
| Total apoptotic CD4+ cell count |          |         |          |         |
| WBCs count               | 0.09     | .66     | 0.47     | .05     |
| Eosinophil count         | −0.26    | .26     | 0.25     | .31     |
| Neutrophil count         | 0.22     | .35     | 0.67     | .003    |
| Lymphocyte count         | 0.29     | .17     | 0.003    | .98     |
| Neutrophil/lymphocyte count | −0.24 |   .3   | −0.58    | .01     |
| Platelet count           | −0.52    | .009    | –        | –       |
| Ferritin level           | 0.52     | .008    | –        | –       |
| D-dimer                  | 0.21     | .32     | –        | –       |
| CRP                      | 0.47     | .02     | –        | –       |
| HbA1C                    | 0.39     | .08     | –        | –       |
| Total apoptotic CD8+ cell count | 0.34 | .1       | 0.73     | .001    |
| WBCs count               | −0.11    | .62     | 0.15     | .62     |
| Eosinophil count         | 0.26     | .26     | 0.25     | .33     |
| Neutrophil count         | 0.78     | <.001   | 0.84     | <.001   |
| Lymphocyte count         | 0.29     | .21     | 0.6      | .012    |
| Neutrophil/lymphocyte count | −0.53 |   .008 | –        | –       |
| Platelet count           | 0.09     | .66     | –        | –       |
| Ferritin level           | 0.08     | .72     | –        | –       |
| D-dimer                  | 0.07     | .69     | –        | –       |
| CRP                      | 0.04     | .84     | –        | –       |
| HbA1C                    | 0.08     | .84     | –        | –       |
| Total CD4+ CTLA-4 cell count | 0.13 | .55       | 0.31     | .2      |
| WBCs count               | 0.4      | .39     | 0.35     | .15     |
| Eosinophil count         | 0.22     | .35     | 0.003    | .98     |
| Neutrophil count         | 0.4      | .05     | 0.45     | .006    |
| Lymphocyte count         | 0.29     | .34     | 0.003    | .98     |
| Neutrophil/lymphocyte count | −0.53 |   .008 | –        | –       |
| Platelet count           | 0.32     | .13     | –        | –       |
| Ferritin level           | 0.17     | .41     | –        | –       |
| D-dimer                  | 0.4      | .05     | –        | –       |
| CRP                      | 0.35     | .12     | –        | –       |
| HbA1C                    | 0.1      | .64     | 0.68     | .002    |
| Total CD8+ CTLA-4 cell count | 0.13 | .55       | 0.31     | .2      |
| WBCs count               | −0.13    | .58     | 0.31     | .22     |
| Eosinophil count         | 0.003    | .98     | 0.59     | .009    |
| Neutrophil count         | 0.59     | .01     | 0.48     | .014    |
| Lymphocyte count         | −0.22    | .35     | 0.003    | .98     |
| Neutrophil/lymphocyte count | −0.18 |   .38 | –        | –       |
| Platelet count           | 0.003    | .9      | –        | –       |
| Ferritin level           | 0.19     | .38     | –        | –       |
| D-dimer                  | 0.29     | .16     | –        | –       |
| CRP                      | −0.18    | .38     | –        | –       |
| HbA1C                    | 0.21     | .36     | –        | –       |

CD4 = cluster of differentiation 4, CD8 = cluster of differentiation 8, COVID-19 = coronavirus infectious disease 2019 novel coronavirus, CTLA-4 = cytotoxic T-lymphocyte antigen-4, CRP = C-reactive protein, WBCs = white blood cells.
chest CT score: $R^2 = 0.258$, $P = .015$, respectively; CD152 CD4+: dyspnea duration: $R^2 = 0.375$, $P = .002$ and chest CT score: $R^2 = 0.261$, $P = .012$, respectively).

3.7. Relation between apoptotic and CTLA-4 (CD152) expressing CD4+/CD8+ cells in COVID-19 patients

Total apoptotic cells in CD4+/CD8+ cells proportionally correlated with their CTLA-4, furthermore, both total apoptotic and CTLA-4+CD4+ cells proportionally correlate with that of CD8+ cells (Fig. 2).

3.8. Regression analysis for COVID-19 patients and healthy controls

Regression analysis for COVID-19 revealed that WBCs (X10$^3$/µL), eosinophils (ratio and count), lymphocyte ratio, neutrophil ratio, neutrophil/lymphocyte ratio, neutrophil/CD4 ratio, neutrophil/CD8 ratio CD4+ cells ratio, and CTLA-4+ cells percentage) and CD8+ cells (ratio, count, total apoptotic cells and CD152+ cells) were significantly associated with COVID-19 using univariable analysis, but none of them was detected as an independent factor using multivariable analysis (Table 4).

4. Discussion

Current data on the contribution of T cells in COVID-19 pathogenesis is limited and inconsistent. Some reports attribute lung injury to T cells' high cytotoxic activity rather than a defective T cell response. An autopsy study proposed that direct infection of ACE2-expressing macrophages may result in activation-induced T cell apoptosis.[22] On the other hand, lymphopenia in COVID-19 patients may contribute to the severe disease being a probable cause of functional T cell exhaustion, principally in elderly and critically ill patients.[8]

Figure 2. Correlations of total apoptotic and CD152 expressing CD4 and CD8 cells and laboratory parameters in COVID-19 patients (A) and healthy controls (B). CD4 = cluster of differentiation 4, CD8 = cluster of differentiation 8, COVID-19 = coronavirus infectious disease 2019 novel coronavirus.
We analyzed the total apoptotic cells and CTLA-4 expression among CD4 and CD8 cells in patients with confirmed symptomatic COVID-19 and compared this data with that of normal individuals. Consistent with previous studies,[8,23,24] our results showed that both the CD4⁺ and CD8⁺ absolute cell counts and percentages showed a marked reduction in COVID-19 patients compared to healthy controls. A higher neutrophil/lymphocyte ratio is also reported in those critically ill patients during the critical stages, reflecting the serious disturbance of their internal environment.

Virus-induced direct cytopathic effects are believed to play a major role in disease severity.[25] A rapid innate immune response is crucial against viral infections. However, if it is not well coordinated, excessive inflammation and even death can occur.[3] In addition, pronounced CD3⁺ and CD4⁺ lymphopenia were observed in severe cases of COVID-19 cases, which may be the reason for aggravated inflammatory responses, cytokine storm production, and tissue damage. Although not conclusive, correlative evidence from those severe COVID-19 patients with lymphocyte reduction suggests a role for dysregulated immune responses in disease pathogenesis. Our results are also consistent with Hu et al, who reported reduced CD3⁺ T cells and their CD4⁺ and CD8⁺ cell subsets in the dead pneumonic group compared with the surviving group, suggesting the activation and depletion of T cells in the antiviral process.[24] Similarly, Channappanavar et al, and others reported up to 100% of COVID-19 patients showing marked CD4 lymphopenia[34] and 87%, 76%, and 55% showing CD8, B cells, and NK cell decrease, respectively.[3] Consistent with Wang,[7] except for the CD4/CD8 ratio, we did not find statistically significant differences between the 2 groups. Studies with bigger sample size are needed to better understand lymphocyte subset dysregulation and CD4/CD8 ratio roles in COVID-19 pathogenesis and their therapeutic implications.

Further analysis of COVID-19 cases enrolled in our study revealed that total apoptotic CD4⁺ and CD8⁺ cells as well as
in eliciting apoptosis in CD4+ T cells but not CD8+ T cells in the context of COVID-19, causing the profound T cell lymphopenia observed in those patients.

Even though in normal individuals, activated CD8 killer T cells express CTLA-4, higher levels are expressed by CD4+ T cells.[25] The primary physiologic role of CTLA-4 appears to be via its preferential effects on CD4+ T cell subsets.[26] This suggests that targeting CTLA-4 favorably affects the CD4+ T-cell function.[27,28]

Jeannet and others reported that CD4 T cells showed increased CTLA-4 and programmed death-1 (PD1) expression levels in severe COVID-19 patients, while CD8 T cells, which persistently expressed PD-1, didn’t show a significant change in CTLA-4 expression.[29] In addition, An earlier study on HIV stated that unlike CD4+ T cells, CTLA-4 expression by CD8+ T cells was always low and that CD8 impaired responses to B7 co-stimuli were due to CD28 downregulation rather than increased CTLA-4 expression.[30]

Patients with severe COVID-19 exhibit lymphocytopenia and suffer from T-cell exhaustion. Based on observations that stemmed from the use of immune-checkpoint inhibitors in medical oncology, antibodies blocking the PD-1/PD ligand-1 (PD-L1) axis have given new hope for restoring T-cell competence and efficiently counteracting the SARS-CoV2 infection. Several clinical trials are currently open to examine the efficacy of anti-PD-1 antibody in COVID-19 individuals.[31]

Moreover, our results showed that ferritin and CRP levels had positive relations with the levels of the total apoptotic CD4+ cells. And These relations may reflect the presence of a possible link between apoptotic T cell levels and the extensive inflammatory reaction observed in severe cases. In addition, negative correlation observed between CD4+ CD152+ cell count and platelet count and CRP in COVID-19 patients can increase the chances of the possible anti-inflammatory effect of CD152 marker.

Strengths and limitations: our study is the first to investigate the relation between apoptosis and CD152 expression among CD4 and CD8 cells in COVID-19 and their relation with some severity indicators. However, further evaluation in larger studies, with a further investigation for other markers of apoptosis as CD95 and its mediators, may result in a better understanding of COVID19 pathogenesis and complications, which would help in tailoring a more effective therapy.

5. Conclusion
The present study showed increased apoptosis and CTLA-4 expression by CD4+ and CD8+ cells in COVID-19 patients. Besides, CTLA-4 and total apoptotic CD4+/CD8+ cell correlation that is related to clinical severity, proposes that CTLA-4 and total apoptotic cells can be used as reliable markers for diagnosis and prognosis of COVID-19 and can further be promising future targets for immune therapy.

The limitations of our study the small sample size and inability to measure other inflammatory markers as IL-6, to reduce the expenses in the epidemic times, no exclusion of natural killer cells inside CD4+ and CD8+ due to the limited gating strategies in FACsCalibur.

Acknowledgments
All thanks go to all participants who voluntarily donated their samples.

Author contributions
Conceptualization: Asmaa M. Zahran, Heba Ahmed Osman, Asmaa Nafady.
Data citation: Hanaa Nafady-Hego, Alaa Rashad, Omnia El-Badawy, Khalid Ali Nasif.

Formal analysis: Amr Talat Mostafa, Abdelkader Ahmed Hashim, Nehad Hassan Abd Elrahman.

Investigation: Asmaa M. Zahran, Asmaa Nafady, Hanaa Nafady-Hego, Eptehal Mohammed Dongol, Ghada M. Abdelrazek, Amr Talat Mostafa.

Methodology: Asmaa M. Zahran, Hanaa Nafady-Hego, Alaa Rashad, Omnia El-Badawy, Khalid Ali Nasif, Amr Talat Mostafa, Heba Ahmed Osman, Eptehal Mohammed Dongol Abdelkader Ahmed Hashim, Ghada M. Abdelrazek, Nehad Hassan Abd Elrahman, Asmaa Nafady.

Project administration: Asmaa Nafady, Asmaa M. Zahran, Heba Ahmed Osman.

Writing – original draft: Hanaa Nafady-Hego, Amr Talat Mostafa, Heba Ahmed Osman, Eptehal Mohammed Dongol Abdelkader Ahmed Hashim, Ghada M. Abdelrazek, Nehad Hassan Abd Elrahman, Asmaa Nafady.

Writing – review & editing: Asmaa M. Zahran, Hanaa Nafady-Hego, Alaa Rashad, Omnia El-Badawy, Khalid Ali Nasif, Abd Elrahman, Asmaa Nafady.

Methodology: Asmaa M. Zahran, Hanaa Nafady-Hego, Alaa Rashad, Omnia El-Badawy, Khalid Ali Nasif, Amr Talat Mostafa, Heba Ahmed Osman, Eptehal Mohammed Dongol Abdelkader Ahmed Hashim, Ghada M. Abdelrazek, Nehad Hassan Abd Elrahman, Asmaa Nafady.

Project administration: Asmaa Nafady, Asmaa M. Zahran, Heba Ahmed Osman.

Writing – original draft: Hanaa Nafady-Hego, Amr Talat Mostafa, Heba Ahmed Osman, Eptehal Mohammed Dongol Abdelkader Ahmed Hashim, Ghada M. Abdelrazek, Nehad Hassan Abd Elrahman, Asmaa Nafady.

Writing – review & editing: Asmaa M. Zahran, Hanaa Nafady-Hego, Alaa Rashad, Omnia El-Badawy, Khalid Ali Nasif, Abd Elrahman, Asmaa Nafady.

References

[1] Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–50.
[2] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.
[3] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020;80:607–13.
[4] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhuan, China. Clin Infect Dis. 2020;71:762–8.
[5] Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18:206.
[6] Kong M, Zhang H, Cao X, et al. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148:e139.
[7] Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221:1762–9.
[8] Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
[9] Choudhuri I, Han H, Manthani K, et al. COVID-19 as a possible cause of functional exhaustion of CD4 and CD8 T-cells and persistent cause of methicillin-sensitive staphylococcus aureus bacteremia. Cureus. 2020;12:e9000.
[10] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult patients with COVID-19 in Wuhuan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
[11] McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983;309:13–7.
[12] Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26:842–4.
[13] Leng Z, Zhu R, Hoo W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216–28.
[14] Li FQ, Tam JP, Liu DX. Cell cycle arrest and apoptosis induced by the coronavirus infectious bronchitis virus in the absence of p53. Virology. 2007;365:435–45.
[15] Sumikoshi M, Hashimoto K, Kawasaki Y, et al. Human influenza virus infection and apoptosis induction in human vascular endothelial cells. J Med Virol. 2008;80:1072–8.
[16] Taghisoo S, Aliyali M, Abdi S, et al. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID-19 patients: clinical and laboratory characteristics. J Med Virol. 2020;93:1598–98.
[17] Collins AV, Brodie DW, Gilbert Rj, et al. The interaction properties of costimulatory molecules revisited. Immunity. [Research Support, Non-U.S. Gov't]. 2002;17:201–10.
[18] Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–63.
[19] Robin Jeannet TD, Rémy F, Jean F, et al. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. [LETTER TO THE EDITOR]. 2020;46:3.
[20] Sedeek O, Abdelsalam A, El Hafeez H, et al. Platelet apoptosis in pediatric immune thrombocytopenia. J Curr Med Pract. [Original Article]. 2017;2:192–8.
[21] Badr GZA, Omar HM, Barsoum MA, et al. Camel whey protein disrupts the cross-talk between PI3K and BCL-2 signals and mediates apoptosis in primary acute myeloid leukemia cells. Nutr Cancer. 2019;71:114.
[22] Feng ZDB, Wang R, Wang G, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020.
[23] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. [Research Support, Non-U.S. Gov't]. 2020;368:m1091.
[24] Hu D, Li L, Shi W, et al. Less expression of CD4(+) and CD8(+) T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: evidence from a pooled analysis. Clin Chim Acta. 2020;510:1–4.
[25] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. [Review Research Support, N.I.H., Extramural]. 2017;39:529–39.
[26] Orbach A, Rachmilewitz J, Parnas M, et al. CTLA-4. FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2007;179:7287–94.
[27] Chan DW, Gibson HM, Aufiero BM, et al. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. 2014;15:25–32.
[28] Pandol DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. [Research Support, Non-U.S. Gov't Research Review]. 2012;12:232–64.
[29] Jeannet R, Daux T, Formento R, et al. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. [Letter]. 2020;46:1769–71.
[30] Steiner K, Waase I, Rau T, et al. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells might reflect the severity of infection and predict worse prognosis in patients with COVID-19: evidence from a pooled analysis. Clin Chim Acta. 2020;510:1–4.
[31] Vivarelli S, Falzone L, Torino F, et al. Immune-checkpoint inhibitors from cancer to COVID19: a promising avenue for the treatment of patients with COVID19 (Review). Int J Oncol. [Review]. 2021;58:145–57.